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ABSTRACT 
Objective: Design and evaluation of fluvoxamine loaded bio-nanosuspensions using biopolymer which was isolated from the wood of Santalum 
album used as the stabilizer. 
Methods: The main aim of the present investigation was to obtain an ocular drug delivery system with improved stability using biopolymer. The 
fluvoxamine loaded Bio-nanosuspension was prepared using novel biopolymer isolated from Santalum album by sonication solvent evaporation 
method with different ratios (1%, 2%, 3%, 4% and 5%) and evaluated for particle size, polydispersity index, zeta potential, pH stability studies, 
%entrapment efficacy, in vitro drug release, stability studies. 
Results: The prepared bio-nanosuspension was subjected to the best formulation based on the comparison of above-mentioned evaluation 
parameters, so Fb3 (3%) formulation was found to be the best formulation showing an R2 value of 0.9744, T50% of 31.3 h and T80% of 50.1 h 
respectively. According to the release kinetics, the best fit model was found to be Peppas Korsmeyer with Fickian Diffusion (Higuchi Matrix) as the 
mechanism of drug release. Santalum album provided excellent stability for the formulation, and resulting particle size for the best formulation was 
found to be 196 nm. The bio-nanosuspension had Polydispersity Index (PDI) of 0.19 with zeta potential of-20mV. 
Conclusion: The prepared bio-nanosuspension was found to be safe and compatible with the ophthalmic delivery for treatment of depression. 
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Poorly soluble drugs are very often a challenging problem in drug 
formulation, especially when the drugs are poorly soluble 
simultaneously in aqueous and non-aqueous media. This leads in 
most cases to poor bioavailability or poor erratic absorption of these 
drugs [1, 2]. Many attempts have been made to increase the 
saturation solubility of poorly soluble drugs [3, 4]. Ophthalmic drug 
delivery, more than any other route of administration, may benefit 
to a full extent from the characteristics of Nano-sized drug particles. 
Nanosystems are an emerging part of this strategy. Investigating the 
ocular biodistribution of nanoparticles can provide insights into the 
bioavailability, cellular uptake, duration of drug action, and toxicity. 
Many factors such as particle size, composition, surface charge and 
mode of administration influence the biodistribution in the retinal 
structures and also their drainage from the ocular tissues [8]. 
Nanosuspensions are sub-micron colloidal dispersions of pure drug 
particles in an outer liquid phase [5]. Nanosuspension has 
advantages in various aspects of dosing. Small particle size and large 
surface area can improve the dissolution, saturation solubility and 
bioavailability of the drug [21]. The use of nanosuspension in the 
central nervous system can reduce not only systemic toxicity but 
also increase the concentrations of poorly water-soluble drugs in the 
brain [6, 7]. The Nano-size represents a state of matter characterized 
by higher solubility [9-11], the higher surface area available for 
dissolution [12, 13], higher dissolution rate [15], higher bio 
adhesion [16, 17] and corneal penetration. It has been 
recommended that particles be less than 10 μmto minimize particle 
irritation to the eye, decrease tearing and drainage of instilled dose 
and therefore increase the efficacy of an ocular treatment. Many 
published articles have indicated the importance of particle size in 
ophthalmic bioavailability [17, 18] most of these articles prove that 
decreasing the particle size increases the ophthalmic bioavailability. 
Selective serotonin reuptake inhibitors (SSRIs) are antidepressant 
drugs that increase serotoninergic neurotransmission via the 
selective inhibition of neuronal reuptake of serotonin. SSRIs are 
substituting the older tricyclic antidepressants (TCAs). Because of 
the Selective serotonin reuptake inhibitors (SSRIs) does not show 
significantly variation in the efficacy relative to the TCAs and the 
SSRIs do not show very important extrapyramidal side-effects, they 
are increasingly becoming the drugs of choice in depression remedy. 
In addition to the antidepressant properties of fluvoxamine, 
fluvoxamine is used for the treatment of generalized anxiety 
disorder, obsessive-compulsive disorder, eating disorders, social 
phobia, and anxiety disorders such as post-traumatic stress disorder 
and panic disorder [19]. 
The present study addresses fluvoxamine bio-suspensions in the nano 
range in the form of nanosuspensions using a novel method. Therefore, 
the aim of this study was to understand the impact of processing 
conditions, type and concentration of stabilizers on average particle size, 
size distribution and stability of fluvoxamine nanosuspensions. Although 
fluvoxamine is a sparingly water-soluble drug, it was suitably used in 
this study as a model drug for nanosuspension formulation. 
MATERIALS AND METHODS 
Materials 
Fluvoxamine (assigned purity, 99.8%) was a gift from Lifecare neuro 
Private Limited (Baddi, Himachal Pradesh, India). Santalum album wood 
was purchased from the market of Dehradun, Uttarakhand, India. All 
other chemicals and solvents were of analytical grade. 
Isolation of biopolymer 
200 gm of wood of Santalum album was procured from the market 
and slurry was prepared with 50 ml of distilled water with the help 
of stone plate. Then 150 ml of distilled water was added in 
biomaterial and mixed well and kept in the refrigerator for 24 h. The 
biomaterial was centrifuged at 3000rpm for a period of 15 min, and 
the supernatant was taken and (equal amount of biomaterial) 200 
ml of acetone was added after optimization and kept for 24 h in a 
refrigerator. Then biomaterial was separated from acetone and 
dried in a vacuum desiccator for 14h. The dried biomaterial was 
purified by the hot dialysis method using an ORCHID scientific 
dialysis apparatus for complete removal of impurities like chlorides 
and sulphates. The procedure was optimized by repeating six times 
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and the percentage yield was calculated. The purified biopolymer 
was screened through 200#mesh and stored for later use. 
Characterization of biopolymer 
The isolated biomaterial was subjected to Infra-red Spectroscopy (IR), 
Differential scanning calorimetry (DSC), Scanning electron microscopy 
(SEM) and Nuclear magnetic resonance spectroscopy (NMR). 
Preparation of fluvoxamine nanoparticles 
Fluvoxamine nanoparticles were prepared by the modified solvent 
evaporation method. The solution of drug (the specified amount) and 
methanol was prepared and sonicated for 30 cycles (3 min./cycle in 
ultrasonic bath sonicator). Till the solution become turbid and then 
sonicated again. The resulting solution was then centrifuged at 3000 
rpm for 20 min. The nanoparticles obtained were collected and 
washed with distilled water and dried at room temperature. 
Characterization of fluvoxamine nanoparticles 
The prepared nanoparticles were subjected to particle size analysis, 
polydispersity index and zeta potential. The zeta potential, particle 
size and the size distribution of the fluvoxamine nanoparticle was 
measured using Malvern zeta sizer 2000, UK. The surface charge 
determination was performed using an aqueous dip cell in an 
automatic mode by placing diluted samples in the capillary 
measurement cell, and cell position was adjusted. 
Preparation of bio-nanosuspensions 
The fluvoxamine loaded Bio-nanosuspensions were prepared using 
novel biopolymer isolated from the wood of Santalum album as bio-
stabilizer by sonication solvent evaporation method. Nanosized 
biopolymer (1%, 2%, 3%, 4%, 5%) was taken in Glass mortar with 
nanosized drug (10 mg), 1% of dextrose and 0.9%sodium chloride 
(isotonic agent), 0.1% of Polyvinyl alcohol (PVA) (as a lubricant and 
antiaggregant) and the mixture was triturated properly for 2 min. 
After that 10 ml of distilled water was added and the mixture was 
triturated in a uniform direction. The resulting solution was kept on 
the magnetic stirrer for 30 min and then subjected for sonication at 
(10cycle) for 30 min to prepared bio-nanosuspension. Similarly, 
various formulations with different ratios were prepared by varying 
concentration of the biopolymer. 
 
Table 1: Preparation formula of bio-nanosuspensions with different five ratios 
S. No. Formula Fb1 Fb2 Fb3 Fb4 Fb5 
1. Fluvoxamine (mg) 10 10 10 10 10 
2. Santalum albumbiopolymer 1% 2% 3% 4% 5% 
3. Dextrose 5% 5% 5% 5% 5% 
4.  Poly vinyl alcohol (PVA) 0.1% 0.1% 0.1% 0.1% 0.1% 
5. Sodium chloride 0.9% 0.9% 0.9% 0.9% 0.9% 
6.  Benzalkonium chloride 0.5% 0.5% 0.5% 0.5% 0.5% 
7. Distilled water (mL) 10 10 10 10 10 
 
Characterization of drug-loaded bio-nano suspensions 
The bio-nanosuspensions were evaluated for particle size, poly-
dispersity index, zeta potential, pH stability studies, % entrapment 
efficacy, in vitro drug release, stability studies. 
Particle size distribution and polydispersity index (PDI) 
The average particle size and zeta potential values of the 
nanosuspension batches were measured using a Malvern Zetasizer 
Nano ZS90(Malvern Instruments) which were carried out at 25 °C 
using plain folded capillary zeta cells. The diluted samples were 
placed directly into the cuvette, and the data were collected for 10 
times. All experiments were performed in triplicates, and the 
average value was used from each set of data. 
Determination of zeta potential 
PDI values were measured to understand the size distribution of the 
nanoparticles and the value range between 0.000 and 1.000, which 
demonstrates narrow to the very wide size distribution of the 
particles. 
pH stability studies 
The pH values were measured at 25 °C using a digital pH meter at 
20±1 ◦C. The formulation was brought in contact with the electrode 
of pH meter and equilibrated for 1 min. This method was done in 
triplicate and mean was calculated along with standard deviation. 
% Entrapment efficacy 
The freshly prepared nanosuspension was centrifuged at 20,000 
rpm for 20 min at 5 °C temperature using cool ultracentrifuge. The 
amount of unincorporated drug was measured by taking the 
absorbance of the appropriately diluted 25 ml of supernatant 
solution at 268 nm using UV spectrophotometer against 
blank/control nanosuspensions. DEE was calculated by subtracting 
the amount of free drug in the supernatant from the initial amount 
of drug taken. The experiment was performed in triplicate for each 
batch, and the average was calculated [20]. The entrapment 
efficiency (EE %) could be achieved by the following equation 1:  
% Entrapment efficiency
= Total drug − free drug × 100 ÷ Total drug 
In vitro drug release studies 
The in vitro drug diffusion assay was carried out in the M. S. 
diffusion apparatus. This was a static method and requires complete 
replacement of the sample. Dialysis membrane was tied to the the 
terminal portion of the cylindrical donor compartment. 2 ml of bio-
nanosuspension was kept above the dialysis membrane in the donor 
compartment, and the receiver compartment was filled with a 
diffusion medium. The complete sample was withdrawn at different 
time intervals, and the receiver compartment was refilled with fresh 
medium. The amount of drug released was assessed by measuring 
the absorbance at 268 nm using UV spectrophotometer. 
Stability studies 
Stability of the fluvoxamine nanosuspensions was investigated for six 
months at the ambient condition to monitor the change in appearance, 
physical characteristics and release behavior. Two portions of 
fluvoxamine nanosuspensions from the same batch were kept under 
two different conditions (25 °C, 60% RH and 40 °C, 75% RH). 
Statistical analysis 
The graph software “Design expert 11” was applied to explore the 
significance of the data. The one way ANOVA test followed by post-
hoc analysis was employed to compare the particle size and 
entrapment efficacy. A value of p<0.05 was considered significant 
for the data obtained from the study. 
RESULTS AND DISCUSSION 
Isolation of the biomaterial  
The biopolymer was isolated from by simplified economic process. The 
optimization of the biopolymer isolation process was repeated six times 
for, and the % yield was calculated. During optimization, the results 
obtained were reproducible with insignificant variation and can be 
adopted for scaling up in a bulk manner. The % yield for biomaterial 
from leaves of Santalum album was found to be of 10% w/w. 
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Characterization of biopolymer 
IR spectroscopy 
The result of IR spectra of biopolymer isolated from Santalum 
album(White sandalwood) showed revealed the presence of esters 
(1389 cm-1), alkenes (3124 cm-1), a hydroxyl group (2736 cm-1) 
and carboxylic acid (3163 cm-1). These functional groups are 
responsible for adhesion activity of the biopolymer as these same 
groups are observed in polymer-like HPMC and Eudragit (fig. 1) 
Differential scanning calorimetry (DSC) 
The Santalum album showed sharp endothermic transitions at ∼102 °C. 
Biopolymer was shown to be the most effective stabilizers in all the 
characterization studies (fig. 2). 
 
 
Fig. 1: IR spectroscopy of biopolymer Santalum album 
 
 
Fig. 2: DSC of biopolymer Santalum album 
 
 
Fig. 3: SEM of biopolymer Santalum album 
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Scanning electron microscopy (SEM) 
The topology of biopolymer isolated from Santalum album (White 
sandalwood) observed irregular, smooth, pletigranule surface 
topology with 10μm in size at 1,000 magnifications. This clearly 
indicates it is granular and polymeric in nature (fig. 3). 
Nuclear magnetic resonance (NMR) 
The NMR spectra of biopolymer isolated from Santalum 
album(White sandalwood) revealed that the peaks were found to 
be 27.021 ppm which showed presence of C-C, 79.063 ppm 
which showed presence of C-O, 119.05 ppm which showed 
presence of C=C, 143.41 ppm which showed presence of C=C, 
155.88 ppm which showed presence of C=O preferably. Hence it 
clearly indicated that bio-polymer was polymeric in nature 
(fig. 4). 
Characterization of fluvoxamine nanoparticles 
Particle size distribution and polydispersity index (PDI) 
The z-particle size of fluvoxamine nanoparticles was found 368 nm. 
The polydispersity index (PDI) of 0.56 indicating narrow size 
distribution. Particle size distribution graph for Fluvoxamine 
nanoparticles is shown in fig. 5. 
 
 
Fig. 4: NMR of biopolymer Santalum album 
 
 
Fig. 5: Particle size and size distribution of fluvoxamine nanoparticle 
 
 
Fig. 6: Zeta potential and size distribution of fluvoxamine nanoparticles 
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Determination of zeta potential 
The electric charge present on the nanoparticles was evaluated by 
measuring the zeta potential as shown in fig. 6. Zeta potential of 
nanoparticles was-7.96 mV which indicates significant stability with 
no agglomeration. 
Characterization of drug-loaded bio-nano suspensions 
Particle size distribution and polydispersity index (PDI) 
The particle size of fluvoxamine was analyzed by Malvern Zetasizer. 
The z-particle size of bio-nanosuspension was found 196 nm. The 
ability of nanoparticles to alter the biodistribution and pharmaco-
kinetics of drug has important in vivo therapeutic application. So, the 
size and surface characteristics of nanoparticles are of prime 
important. Nanoparticles ranging 200 nm are easily captured by 
Kupffer cells or other phagocytic cell population that restrict 
biodistribution. These systems help in prolonging the duration of 
drug activity and increase the targeting efficiencies to the specific 
site. Particle size distribution graph for formulation (FB3) is shown 
in fig. 7. Polydispersity index (PDI) of 0.19 indicating narrowest size 
distribution. The PDI is the measure of a size distribution of the 
nanoparticles, where it less than 0.5 indicates monodisperse size 
distribution. These data also support the results observed using 
microscopic methods in the current study and suggest that 
nanosization was achieved for bio-nanosuspension. 
 
 
Fig. 7: Particle size and size distribution of fluvoxamine bio-nanosuspension 
 
Determination of zeta potential 
The electric charge present on the bio-nanosuspension was 
evaluated by measuring the zeta potential as shown in fig. 8. Zeta 
potential of the formulation (FB3) was-20.1 mV which indicates 
significant stability with no agglomeration. The value of particle 
surface charge indicates the stability of nanosuspensions at the 
macroscopic level. A minimum zeta potential of±30 mV is required 
for electrostatically stabilized nanosuspensions and a minimum 
of±20 mV for steric stabilization. The zeta potential values are 
commonly calculated by determining the particle's electrophoretic 
mobility and then converting the electrophoretic mobility to the zeta 
potential. An electroacoustic technique is also used for the 
determination of the zeta potential in the areas of material sciences. 
 
 
Fig. 8: Zeta potential and size distribution of fluvoxamine bio-nanosuspension 
 
pH stability studies 
The pH of the fluvoxamine loaded bio-nanosuspensions 
prepared using biomaterial isolated from the wood of Santalum 
album (white sandalwood) (FB1-FB5) were found in the range of 
7.3 to 7.8. (fig. 9)  
% Entrapment efficacy 
The entrapment efficacy of the fluvoxamine loaded bio-
nanosuspensions prepared using biomaterial isolated from the 
wood of Santalum album (white sandalwood) (FB1-FB5) were found 
in the range of 63.8%-89.7 % (fig. 10). 
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Fig. 9: pH stability studies of fluvoxamine bio-nano suspensions, mean of three observation±SD (n=3) 
 
 
Fig. 10: % Entrapment efficacy of fluvoxamine bio-nanosuspension, mean of three observation±SD (n=3) 
 
In vitro drug release studies 
In vitro, drug release studies were performed for all the 
formulations. The mechanism of fluvoxamine released from the bio-
nanosuspensions was studied by fitting the release data in different 
kinetic models such as Zero order, First order, Higuchi Matrix, 
Peppas Korsmeyer and Hixon Crowell and determining the R2 values 
of the release profile corresponding to each model. Its % drug 
release, T50%% andT80%% were calculated and based on other 
parameters were arranged in decreased manner. The drug release 
pattern for formulationsFb1-Fb5containing biomaterial isolated 
from the wood of Santalum album (white sandalwood) based on the 
T50% and T80%was found to be Fb3 (3%)>Fb4 
(4%)>Fb1(1%)>Fb2 (2%)>Fb5 (5%). In vitro drug release was 
performed for all the formulations and the data indicate that drug-
loaded formulations show the sustained release behavior. Graph 
was plotted between %CDR and time, the R2 value, T50% and T80% 
was calculated from graph, the Fb3 (3%) formulation was found to 
be the best formulation showing an R2 value of 0.9744, T50% of 31.3 
h and T80% of 50.1 h respectively. According to the release kinetics, 
the best fit model was found to be Peppas Korsmeyer with Fickian 
Diffusion (Higuchi Matrix) as the mechanism of drug release (fig. 11) 
 
 
Fig. 11: In vitro drug release of bio-nanosuspensions, mean of three observation±SD (n=3) 
 
Stability studies 
At the end of the stability study, the formulated bio-
nanosuspension showed little to no drug loss. The bio-
nanosuspension also showed an insignificant difference for in 
vitro drug release. All optimized formulation showed satisfactory 
drug release and other properties during and at the end of the 
accelerated stability period. This indicates that there was no 
influence on the chemical and physical stability of the 
formulation during the test period. 
Tyagi et al. 
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This biopolymer has the desired properties for safe use in 
biomedicine, Santlum album biopolymer as a bio-stabilizer and bio-
retardant has considered as a promising material for the 
development of safe and effective drug delivery systems owing to 
their unique physicochemical characteristics. Being mucoadhesive 
polymer, this biopolymer enhances the residence time of the of the 
system and consequently the bioavailability of the drug. 
CONCLUSION 
The fluvoxamine bio-nano suspensions prepared by sonication 
solvent evaporation method. Santalum album provided excellent 
stability for the formulation and resulting particle size for best 
formulation 196 nm. The bio-nanosuspension had PDI of 0.19 with zeta 
potential of-20mV. The prepared bio-nanosuspensions were found to be 
safe and compatible with the ophthalmic delivery for treatment of 
depression, and this is a novelistic approach significantly delivering the 
drug for a prolonged period, and the biopolymer was served as a 
promising excipient for delivering dosage forms. 
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